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ABSTRACT: The objective of this present work was to 
develop and validate analytical method for quantitative 
determination of Paracetamol and Etoricoxib in a tablet 
formulation and also the comparison of invitro data with 
reference dosage form. Chromatographic separations of the 
two drugs were analyzed on a Kromasil C18 column (25cm 
X 4.6mm, 5 m). The mobile phase constituted of Buffer: 
Acetonitirile with gradient program was delivered at the 
flow rate 1.0 mL/min. Detection was performed at 220 nm. 
Separation was completed within 20 min. Calibration 
curves were linear with coefficient correlation between 
0.99 to 1.0 over a concentration range of 48 to 146 g/mL 
of Paracetamol and 6 to 19 g/mL for Etoricoxib 
respectively. The relative standard deviation (R.S.D) was 
found to be less than 2.0%. Analysis for dissolution study 
was also performed by Reversed-Phase High Performance 
Liquid Chromatography (RP-HPLC) method. Difference 
factor (f1) were found to be 2.85 and 3.83 and similarity 
factor (f2) were found to be 73.514 and 68.961 for 
Paracetamol and Etoricoxib respectively. 
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The combination tablet consists of Etoricoxib 60 mg and 
Parcetamol 500 mg. Non-Steroidal anti-inflammatory drugs 
are widely used for the treatment of pain, inflammation, 
and fever. Pharmacological action of drug of Etoricoxib is 
due to selective inhibition of cyclooxygenase-2 (COX-2), 
which block the prostaglandin synthesis1-5. Cyclooxygenase 
exist in two forms COX-1 and COX-2. COX –1 is having 
good action like protection of GI mucosa, maintenance of 
renal homeostasis, platelet aggregation. On the other hand 
COX-2 is responsible for prostaglandin synthesis, which 
leads to cause Pain, Inflammation, and Fever. Paracetamol 
(Acetaminophen) is Para-aminophenol derivative and is 
deethylated active metabolite of Phenactin. Paracetamol is 
commonly used for mild to moderate pain and having poor 
anti-inflammatory action. Paracetamol inhibit the 





           
It is establish clinical practice to combine NSAIDS with 
Paracetamol for their synergistic analgesic activity. Since 
both the drugs have distinct mechanism of action. Further 
addition of Paracetamol provides additional antipyretic 
effect. Since fixed dose combinations of COX-2 inhibitors 
with Paracetamol are used for short –term treatment of 
acute pain only, their safety would not be matter of 
concern. Further US-FDA advisory committee has 
recommended the reintroduction of roficoxib in the US 
market6. The method for analyzing Etoricoxib in plasma7, 8, 
impurity analysis and validation9 by HPLC and UV10 is 
already published in different journals while assay of 
paracetamol API and tablet is official in all 
Pharmacopoeia11,12. Simultaneous analysis of Etoricoxib 
with paracetamol is not published in any journal and its 
combination is yet to launch in the market. Dissolution test 
of conventional dosage forms provides useful 
recommendation for their evaluation. Different official 
apparatus are available. Assay method was validated as per 
the procedure and acceptance criteria based on FDA 
guideline13 and recommendation of ICH 14. The validation 
of dissolution test can be divided into two parts. The first 
regards equipment validation and second concerns method 
precision validation. There is no official method for 
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determination of dissolution rate of both these components 
in tablet dosage form. A review of the literature indicated 
that there was no reported dissolution method for this 
combination product.  
 
MATERIAL AND METHODS: 
Chemicals and Materials: Cadila Healthcare Limited, 
Patalganga supplied Etoricoxib and Granules India limited 
supplied Paracetamol. Acetonitrile and Trifluoroacetic acid 
were obtained from Spectrochem and E-Merck Limited 
respectively. 
Instrumentation: 
Shimadzu 2010C integrated high performance liquid 
chromatographic system was used for this experiment. 
Shimadzu 2010C system equipped with quaternary gradient 
pump, 2010C UV-VIS detector, 2010C Column Oven and 
2010C programmable auto sampler controlled by CLASS-
VP software. The Kromasil C18 (250X4.6 mm), 5µm was 
used as a stationary phase.  Electrolab autosampler 
dissolution apparatus were used for comparative dissolution 
study. 
HPLC Condition: 
Column   Kromasil C18 (250X4.6 mm), 5µm 
Detector   220 nm 
Injection volume  20 µL (Assay) and 50 µL (Dissolution) 
Flow rate   1.0 ml/min 
Temperature   30˚ C 
Run time  22 min 
Diluent   Buffer: Acetonitrile (75: 25) 
Mobile phase   Gradient programme 
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Buffer preparation:  
Take 1.0 ml of Trifluroacetic acid in to 2000 ml of Milli Q 
water and mix. Filter it through 0.45 um HVLP filter paper 
and degassed. 
Media preparation: 
Take 8.5 ml of concentrated hydrochloric acid in to 1000 
ml of DM water and mix.  
For Assay 
Standard preparation: 
Standard stock solutions were prepared in methanol and 
further for second dilution, dilute it with diluent to make 
final concentration Etoricoxib 12.5 g and Paracetamol 100 
g respectively. 
Sample preparation: 
Weigh accurately tablets powdered equivalent to about 150 
mg of Etoricoxib and 1225 mg of Paracetamol in to 250-ml 
volumetric flask. Add about 150-ml methanol and sonicate 
it for 45 minute to dissolve. Filtered it through 0.45 µ 
HVLP nylon filter and made further dilution 2.0 mL to 
100.0 mL with diluent and mix. 
For Dissolution 
Standard preparation: 
Standard stock solutions were prepared in methanol and 
further for second dilution, dilute it with media to make 
final concentration Etoricoxib 12.5 g and Paracetamol 100 
g respectively. 
Sample preparation:  
Dissolution studies on the combination drug of Paracetamol 
and Etoricoxib were conducted using Apparatus II. The 
dissolution medium was 0.1 N Hcl at 37 ± 0.5 C and stirred 
at 100 rpm. In both the experiments 10-ml of sample were 
withdrawn at 30, 45, 60minutes and replacement with the 
equal volume of the fresh medium to maintain the constant 
volume total volume. Second dilutions were done by 
Transferring 2 ml the filtered test solution in 25 ml of 
volumetric flask and volume was make upto the mark with 
fresh media. 
RESULTS:  
The detection wavelength of 220 nm was chosen in order to 
achieve a good sensitivity for quantitative determination of 
Etoricoxib and Paracetamol in tablet dosage. The mobile 
phase consisting of Buffer: Acetonitirile offered a good 
separation at ambient temperature under these conditions 
using a flow rate of 1.0 mL/min and a runtime of 22 min. 
Paracetamol elutes at first and then Etoricoxib shown in the 
chromatogram, Fig. 1 and 2, which illustrate the separation 
of both active ingredients in this system. The model-
independent method was applied to compare the dissolution 
data. By this method dissimilarity factor (f1) were found to 
be 2.85 and 3.83 and similarity factor (f2) were found to be 
73.514 and 68.961 for Paracetamol and Etoricoxib 
respectively. The gradient program throughout HPLC 
method was adopted to analyze both components in a 
single run. The proposed method was simple and do not 
involve laborious time-consuming sample preparation.   
System suitability and system precision: 
System suitability and system precision was daily 
performed during entire validation of this method. The 
results of system suitability and system precision were 
presented in table 1. 
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Linearity and calibration curve: 
The plot of peak area response against concentration was 
shown in Fig 3. The plot is linear over the concentration 
range of 48 to 146 g/mL and 6 to 19 g / mL for 
Paracetamol and Etoricoxib respectively. Linearity of the 
calibration curve was determined by weighed (1/c) least 
square regression analysis. The correlation coefficient was 
found to be 0.99 to 1.00. A linear relationship was found 
for all components. The results of linearity, limit of 
detection and limit of quantification were presented in table 
2. 
Specificity: 
There was no interference from sample placebo and peak 
purity of Paracetamol and Etoricoxib were 1.000 and 1.000 
respectively. It showed that developed analytical method 
was specific for the analysis of Paracetamol and Etoricoxib 
in tablet dosage form.  
Standard and sample solution stability: 
Standard and sample solution stability was evaluated at 
room temperature for 36 h. The relative standard deviation 
was found below 2.0%. It showed that both standard and 
sample solution was stable up to 36 h at room temperature.  
Method precision: 
The precision of the method was established by carrying 
out the analysis of the analyte (n=6) using the proposed 
method. The low value of standard deviation showed that 
the method was precise. The results obtained were 
presented in table 3. 
Method accuracy: 
To ensure the reliability and accuracy of the method 
recovery studies were carried out at three different levels. 
The results of recovery studies were presented in table 4. 
Method robustness: 
Robustness of the method was determined by small 
deliberate changes in flow rate, mobile phase ratio and 
column oven temperature. The content of the drug was not 
adversely affected by these changes as evident from the 
low value of relative standard deviation indicating that the 
method was robust. The results of robustness were 
presented in table 5. 
Method Ruggedness: 
Ruggedness test was determined between two different 
analysts, instruments and columns. The value of percentage 
RSD was below 2.0% showed ruggedness of developed 
analytical method. The results of ruggedness were 




SYSTEM SUITABILITY AND SYSTEM PRECISION 
 
 
Compound Retention n  k’  R   T  α   
Time     
(Mean ±  
SEM) 
 
Paracetamol 8.34 ±  8428.63 1.76    -  1.08      -  
0.0034 
Etoricoxib 18.45 ± 97043.98 5.11  33.69  1.15  2.90  
0.0036   
 
n= Theoretical plates 
k’= Capacity Factor 
R= Resolution 
T= Asymmetry 



















Compound LOD   LOQ  LinearityCorrelation Residual std. Slope of 
µg/ml  µg/ml  range  co-efficient regression regression 
n=(5)  µg/ml   σ      S 
 
 
Paracetamol 0.973  2.919  48-146  0.99970 5497.122     42796.091 
Etoricoxib   0.250  0.750   6 -19  0.99979 11561.427   83977.007 
 
 
LOD= Limit of detection 
LOQ= Limit of quantification 
 
 




Compound Concentration  Retention time  % Assay  % RSD of   
µg/ml     Mean ± SEM  Mean ± SEM   Assay   
(n=6)   (n=6)   (n=6) 
 
    
Paracetamol  100  8.34 ± 0.1922  100.5 ± 0.1922  0.5 









Level   Drug   Drug   % Assay  % RSD of  
   Added  recovered  (Mean ± SEM)  Assay  
   (mg)  (mg)   (n=3)   (n=3) 
For Paracetamol 
50%   613.6  625.37   101.8 ± 0.0577 0.1  
100%   1224.2  1241.22  101.3 ± 0.1155 0.3  
150%   1838.1  1849.27  100.4 ± 0.1202 0.2 
For Etoricoxib     
50%   75.1  75.68   101.6 ± 0.3175            0.5 
100%   150.3  151.5   101.4 ± 0.2332            0.4  















Compound  % RSD in Normal and Changed condition (n=5) 
 
Temperature  % RSD Normal  % RSD (-5°C) % RSD (+5°C) 
     Paracetamol   0.3   0.2            0.2 
     Etoricoxib            0.9              0.3            0.3 
Flow Rate   % RSD Normal          % RSD (-10%)  % RSD (+10%) 
     Paracetamol           0.3             0.3           0.3 








Compound  % Assay     % RSD of Assay 
   Mean ± SEM (n=6)    (n=6)  
Day 1  Analyst-1, Instrument-1 & Column-1 
 
Paracetamol  100.5 ± 0.1922           0.5 
Etoricoxib   104.7 ± 0.0946     0.2   
 
Day 2  Analyst-2, Instrument-2 & Column-2 
Paracetamol  101.4 ± 0.0051     0.4   




Comparative Dissolution Profile (Paracetamol) 
 Reference 
(Paracetamol Tablet 500 mg) 
Test                           
(Etoricoxib+Paracetamol Tablet) 
Manufactured by Zydus Cadila Limited Zydus Cadila Limited 
Batch No. MD3290 PAET 500/F005 
Apparatus USP Type II, RPM- 50 
Method of Analysis HPLC 
Dissolution medium (I) 900 ml, 0.1 N Hydrochloric acid 
% of Drug release for Paracetamol  
Time in minutes Reference Test 
30 92.6 97.6 
45 95.6 98.0 
60 98.9 98.1 
F1 (Similarity factor) 2.856148 












Comparative Dissolution Profile (Etoricoxib) 
 Reference 
(Etoricoxib Tab 60 mg) 
Test                           
(Etoricoxib+Paracetamol Tab) 
Manufactured by Zydus Cadila Zydus Cadila 
Batch No. MD-3124 PAET- 500/F005 
Apparatus USP Type II, RPM- 50 
Method of Analysis HPLC 
Dissolution medium (I) 0.1 N Hydrochloric acid 
% of Drug release for Etoricoxib Tablet 
Time in min Reference Test 
30 93.3 98.9 
45 95.6 99.6 
60 98.3 99.7 
F1 (Similarity factor) 3.830084 

















The method described enables to the quantification of 
Paracetamol and Etoricoxib. The advantages lie in the 
simplicity of sample preparation and the low costs of 
reagents used. The proposed HPLC conditions ensure 
sufficient resolution and the precise quantification of the 
compounds. Results from statistical analysis of the 
experimental results were indicative of satisfactory 
precision and reproducibility. Hence, this HPLC method 
can be used for routine drug analysis.   
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